Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Andrew Kraft

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/315-8802

    Collapse Research 
    Collapse research activities and funding
    R43CA281394     (KRAFT, ANDREW S)Aug 1, 2023 - Jul 31, 2024
    NIH
    Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
    Role: Principal Investigator
    R21CA241010     (KRAFT, ANDREW S)Jul 1, 2020 - Jun 30, 2022
    NIH
    Regulation of P-Body Formation and mRNA Decapping in Cancer: Control by AKT and Pim Kinase Phosphorylation of EDC3
    Role: Principal Investigator
    R21CA178324     (KRAFT, ANDREW S)Jun 1, 2015 - May 31, 2017
    NIH
    Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer
    Role: Principal Investigator
    R01CA173200     (KRAFT, ANDREW S)Sep 17, 2013 - Jul 31, 2019
    NIH
    Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
    Role: Principal Investigator
    K12CA157688     (LOCKHART, ALBERT CRAIG;WRANGLE, JOHN M)Apr 1, 2013 - Mar 31, 2024
    NIH
    MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program
    Role: Co-Principal Investigator
    R41CA135804     (KRAFT, ANDREW S)Sep 7, 2009 - May 31, 2011
    NIH
    Novel Inhibitors of Pim Protein Kinases
    Role: Principal Investigator
    U54CA143924     (HERBST-KRALOVETZ, MELISSA MARIE)Sep 1, 2009 - Aug 31, 2029
    NIH
    2/2 Partnership for Native American Cancer Prevention
    Role: Co-Principal Investigator
    P30CA138313     (DUBOIS, RAYMOND N.)Apr 1, 2009 - Mar 31, 2029
    NIH
    Medical University of South Carolina - Cancer Center Support Grant
    Role: Co-Principal Investigator
    R01CA104710     (KRAFT, ANDREW S)Mar 1, 2004 - Feb 28, 2009
    NIH
    Mechanisms by which Proteasome Enhance Apoptosis
    Role: Principal Investigator
    R21CA095183     (KRAFT, ANDREW S)Apr 1, 2002 - Mar 31, 2006
    NIH
    Pim 1 protein kinase as a target for drug discovery
    Role: Principal Investigator
    P20CA093282     (KRAFT, ANDREW S)Aug 24, 2001 - Jul 31, 2007
    NIH
    Hollings Cancer Center Planning Grant
    Role: Principal Investigator
    T32CA079446     (ECKHARDT, S. GAIL)Sep 1, 1999 - Jun 30, 2010
    NIH
    Training in Pharmacology of Antineoplastic Agents
    Role: Co-Principal Investigator
    R01CA078631     (KRAFT, ANDREW S)Aug 14, 1998 - Apr 30, 2003
    NIH
    REGULATION OF PROSTATE CANCER PROGRAMMED CELL DEATH
    Role: Principal Investigator
    R21CA068284     (KRAFT, ANDREW S)Sep 15, 1995 - Aug 31, 1998
    NIH
    BRYOSTATIN 1 THERAPY OF METASTATIC MELANOMA
    Role: Principal Investigator
    R03CA066634     (KRAFT, ANDREW S)Apr 25, 1995 - Mar 31, 1997
    NIH
    DIFFERENTIATION THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
    Role: Principal Investigator
    R01DK044741     (KRAFT, ANDREW S)Mar 1, 1992 - Nov 30, 2001
    NIH
    MECHANISM OF ACTION OF GM-CSF
    Role: Principal Investigator
    F06TW001522     (KRAFT, ANDREW S)Jun 5, 1990
    NIH
    THE ROLE OF PROTEIN KINASE C IN MEDIATING N-RAS PROTEIN
    Role: Principal Investigator
    R01CA042533     (KRAFT, ANDREW S)Apr 1, 1986 - Jan 31, 2005
    NIH
    CONTROL OF DIFFERENTIATION OF HUMAN PROMYELOCYTES
    Role: Principal Investigator
    P30CA023074     (THEODORESCU, DAN)Sep 1, 1978 - Jul 31, 2027
    NIH
    University of Arizona Cancer Center - Cancer Center Support Grant
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gnawali GR, Okumura K, Perez K, Gallagher R, Wulfkuhle J, Petricoin EF, Padi SKR, Bearss J, He Z, Wang W, Kraft AS. Synthesis of 2-Oxoquinoline Derivatives as Dual Pim and mTORC Protein Kinase Inhibitors. Med Chem Res. 2022 Jul; 31(7):1154-1175. PMID: 36389181.
      View in: PubMed
    2. Padi SKR, Singh N, Bearss JJ, Olive V, Song JH, Card?-Vila M, Kraft AS, Okumura K. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20505-20510. PMID: 31548394.
      View in: PubMed
    3. Daenthanasanmak A, Wu Y, Iamsawat S, Nguyen HD, Bastian D, Zhang M, Sofi MH, Chatterjee S, Hill EG, Mehrotra S, Kraft AS, Yu XZ. PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest. 2018 07 02; 128(7):2787-2801. PMID: 29781812.
      View in: PubMed
    4. Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, Kraft AS, Warfel NA. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res. 2018 01 01; 24(1):169-180. PMID: 29084916.
      View in: PubMed
    5. Warfel NA, Sainz AG, Song JH, Kraft AS. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther. 2016 07; 15(7):1637-47. PMID: 27196781.
      View in: PubMed
    6. Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA, Kraft AS. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12; 7(15):20152-65. PMID: 26956053.
      View in: PubMed
    7. An N, Xiong Y, LaRue AC, Kraft AS, Cen B. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28. PMID: 26670562.
      View in: PubMed
    8. Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, Beverly LJ. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014 Sep 30; 5(18):8503-14. PMID: 25238262.
      View in: PubMed
    9. Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM, Yu XZ, Mehrotra S. Reducing CD73 expression by IL1?-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59. PMID: 25205101.
      View in: PubMed
    10. Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32. PMID: 24777602.
      View in: PubMed
    11. Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53. PMID: 23652277.
      View in: PubMed
    12. An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS, Kang Y. Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells. 2013 Jun; 31(6):1202-12. PMID: 23495171.
      View in: PubMed
    13. Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 01; 73(11):3402-11. PMID: 23585456.
      View in: PubMed
    14. An N, Kraft AS, Kang Y. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol. 2013 Jan 29; 6:12. PMID: 23360755.
      View in: PubMed
    15. Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4672-81. PMID: 22805308.
      View in: PubMed
    16. Song JH, Kraft AS. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303. PMID: 22080570.
      View in: PubMed
    17. Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24. PMID: 21532336.
      View in: PubMed
    18. Song JH, Kandasamy K, Zemskova M, Lin YW, Kraft AS. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2011 Jan 15; 71(2):506-15. PMID: 21084274.
      View in: PubMed
    19. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37. PMID: 20663873.
      View in: PubMed
    20. Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41. PMID: 20647331.
      View in: PubMed
    21. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28; 115(4):824-33. PMID: 19965690.
      View in: PubMed
    22. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83. PMID: 19509254.
      View in: PubMed
    23. Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009 May; 8(9):846-53. PMID: 19276681.
      View in: PubMed
    24. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86. PMID: 19072652.
      View in: PubMed
    25. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13. PMID: 18599488.
      View in: PubMed
    26. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008 May; 7(5):1091-100. PMID: 18483298.
      View in: PubMed
    27. Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221. PMID: 18053191.
      View in: PubMed
    28. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51. PMID: 16123140.
      View in: PubMed
    29. Biggs JR, Zhang Y, Peterson LF, Garcia M, Zhang DE, Kraft AS. Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res. 2005 Jul; 3(7):391-401. PMID: 16046550.
      View in: PubMed
    30. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8. PMID: 15739208.
      View in: PubMed
    31. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9. PMID: 15767553.
      View in: PubMed
    32. Wang Y, Quon KC, Knee DA, Nesterov A, Kraft AS. RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2005 Feb 15; 65(4):1615-6; author reply 1616-7. PMID: 15735052.
      View in: PubMed
    33. Zhang Y, Biggs JR, Kraft AS. Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem. 2004 Dec 17; 279(51):53116-25. PMID: 15475366.
      View in: PubMed
    34. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2004 Jun 01; 64(11):3922-7. PMID: 15173003.
      View in: PubMed
    35. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, Eltoum IE, Abdulkadir SA. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003 Dec 01; 63(23):8079-84. PMID: 14678956.
      View in: PubMed
    36. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67. PMID: 12954615.
      View in: PubMed
    37. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003 Aug 07; 22(32):4953-63. PMID: 12902978.
      View in: PubMed
    38. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb; 23(1A):167-78. PMID: 12680209.
      View in: PubMed
    Kraft's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (298) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)